Atara Biotherapeutics (ATRA) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 9, 2026, to be held virtually, with record date set as April 14, 2026.

• Four key proposals: election of two directors, advisory vote on executive compensation, amendment to the 2024 Equity Incentive Plan, and ratification of Deloitte & Touche LLP as auditor.

• Proxy materials are available online, and shareholders can vote via internet, phone, or mail.

Voting matters and shareholder proposals

• Election of two directors (AnhCo Nguyen and Nachi Subramanian) for terms expiring at the 2029 Annual Meeting.

• Advisory vote on executive compensation (say-on-pay).

• Approval of amendment to the 2024 Equity Incentive Plan to add 400,000 shares for issuance.

• Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.

• Shareholder proposals for the 2027 meeting must be submitted by December 28, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• Board will reduce to six members after the meeting; majority are independent under Nasdaq rules.

• Chair and CEO roles are separated; Gregory Ciongoli serves as independent chair.

• Board diversity includes women and underrepresented communities; active focus on diversity and inclusion.

• Board met 28 times in 2025; non-employee directors held 22 executive sessions.

• Four standing committees: Audit, Human Capital, Nominating and Corporate Governance, and (until September 2025) Research and Development.